Physician profile
Joseph V Edralin
NPI 1821028655
$2,145.55
in general payments reported to CMS, 2019-2025
14 companies · $373 in 2025
The $373 reported for 2025 was more than what 89% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $107 · 2020: $180 · 2021: $303 · 2022: $365 · 2023: $411 · 2024: $407 · 2025: $373.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,191.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,190.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $860.61 | 2021-2025 | Bexsero, Fluarix Quadrivalent, Rotarix |
| Sobi, INC | $354.13 | 2019-2023 | |
| Cranial Technologies, INC | $289.30 | 2019-2025 | Doc Band |
| Sanofi Pasteur INC. | $182.02 | 2023-2025 | |
| Ultragenyx Pharmaceutical INC. | $92.89 | 2019-2021 | |
| Tris Pharma INC | $91.30 | 2022-2024 | Dyanavel Xr |
| Nestle Healthcare Nutrition INC. | $81.83 | 2021-2023 | |
| Pfizer INC. | $51.62 | 2023-2024 | |
| Lnhc, INC | $28.42 | 2025 | Zelsuvmi |
| Biomarin Pharmaceutical INC. | $27.51 | 2025 | Voxzogo 1.2mg |
| Takeda Pharmaceuticals U.S.A., INC. | $26.70 | 2022 | |
| Verrica Pharmaceuticals INC. | $22.73 | 2024 | Ycanth |
| Phadia US INC. | $18.59 | 2019 | |
| Seqirus USA INC | $17.90 | 2025 | Flucelvax |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Edralin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.